RDD Pharma Ltd
RDD Pharma is a specialty pharmaceutical company focused on developing targeted treatments for diseases of the anorectal region, such as fecal incontinence and pruritus ani. They utilize a high-reward, low-risk business model by repurposing approved drugs and combining them with proprietary drug-delivery technology to achieve faster market entry and patent protection.
Industries
Nr. of Employees
small (1-50)
RDD Pharma Ltd
3 Columbus Circle, 15th Floor, New York, NY 10019
Products
Licensable rectal/local drug‑delivery system
A proprietary rectal/local delivery vehicle developed for precise delivery of therapeutic molecules to the anorectal region; intended to be licensable to partners.
Therapeutic candidate for fecal incontinence (Phase 2a completed)
A development candidate evaluated in a Phase 2a clinical study for fecal incontinence that met its primary endpoint of reduced frequency of incontinence events.
Therapeutic candidate for chronic anal fissure (pivotal Phase 3 enrolled)
A development candidate advanced to a pivotal Phase 3 study in Europe for chronic anal fissure; independent safety monitoring supported ongoing conduct without additional enrollment.
Preclinical compound targeting radiation proctitis
A development program at preclinical stage focused on a pharmacological compound for treatment of radiation-induced proctitis.
Licensable rectal/local drug‑delivery system
A proprietary rectal/local delivery vehicle developed for precise delivery of therapeutic molecules to the anorectal region; intended to be licensable to partners.
Therapeutic candidate for fecal incontinence (Phase 2a completed)
A development candidate evaluated in a Phase 2a clinical study for fecal incontinence that met its primary endpoint of reduced frequency of incontinence events.
Therapeutic candidate for chronic anal fissure (pivotal Phase 3 enrolled)
A development candidate advanced to a pivotal Phase 3 study in Europe for chronic anal fissure; independent safety monitoring supported ongoing conduct without additional enrollment.
Preclinical compound targeting radiation proctitis
A development program at preclinical stage focused on a pharmacological compound for treatment of radiation-induced proctitis.
Services
Licensing of a proprietary rectal/local delivery vehicle designed for targeted delivery to the anorectal region.
Collaborative partnerships to repurpose approved molecules combined with targeted delivery technology for anorectal and gastrointestinal indications.
Licensing of a proprietary rectal/local delivery vehicle designed for targeted delivery to the anorectal region.
Collaborative partnerships to repurpose approved molecules combined with targeted delivery technology for anorectal and gastrointestinal indications.
Expertise Areas
- Clinical trial management
- Drug repurposing and repositioning
- Rectal/local drug‑delivery development
- Pharmaceutical formulation for topical/rectal products
Key Technologies
- Rectal/local drug‑delivery systems
- Drug repurposing methodologies
- Clinical trial execution for Phase II–III
- Preclinical candidate development